$591 | SAVE $104 | Single User
$2423 | SAVE $427 | Site License
$4803 | SAVE $847 | Global License

Pharma and Payers – Building Better Relationships

Pharma and Payers – Building Better Relationships
[Lowest Price Guaranteed: $591]

Published by FirstWord Pharma: 01 Sep 2012 | 25 | In Stock
Related Topics: Diabetes , Drug , Healthcare , Johnson and Johnson , Medical , Pricing , Reimbursement , Sanofi-Aventis , Services



Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines.

In this new environment, regulatory approval of new drugs no longer guarantees favourable pricing and formulary placement. Instead, payers focus increasingly on value to determine pricing and access.

Drug developers need to understand the value review process, and adapt their organisation to engaging payers early in the journey. More profoundly, pharma companies must find ways to evolve their current transactional, and even adversarial, relationships with payers to more collaborative ones. After all, Pharma and payers share the same ultimate goals – to lower costs and improve care.

This new report helps Pharma and payers build a “win-win” relationship; by understanding each other’s needs, and by exploring new opportunities for collaboration.


Report Overview

This extensive report includes a wealth of information and tools that empower Pharma and payers to work together more effectively, with the ultimate goal of offering patients access to life-saving drugs, biologics, and vaccines.

After painting a detailed picture of the current environment (including explaining regional payer systems, and key factors driving change), the report offers a fascinating exploration of “what payers want”. You’ll learn about the primary ways in which payers are measuring outcomes (e.g., QALY, CER, pragmatic clinical trials), and discover best practices in resource allocation, organisation, communication, and accountability.

The report includes real case studies of successful pharma-payer partnerships (such as risk-sharing agreements, clinical outcomes studies), and draws on expert opinions and advice from more than a dozen of the world’s foremost thought leaders and executives in this space.


Key Report Features

  • Detailed insights into what payers want from Pharma (and vice versa)

  • Recent case studies of collaborations between major pharma companies and payers

  • Practical advice on meeting payers’ needs and tackling potential problems

  • Review of the growing influence of patients/consumers

  • Description of different types of payers

  • Guide to the payer frameworks in key markets (US, UK, and the leading European pharma markets: Germany, France)

  • Puchase Reasons

    Key Benefits

  • Learn from successful collaborations between payers and Pharma

  • Understand what payers expect and want from Pharma

  • Improve Pharma-payer communications

  • Optimise your organisational structure to meet payer needs

  • Be aware of potential pitfalls

  • Generate successful drug pricing and formulary placement discussions

  • Be ready for future developments

  • Who Should Read This Report?

  • Pharma executives in Market Access, Pricing, Reimbursement, Strategic Planning, and Marketing

  • Payer executives and representatives, including health insurance providers, government payers, pharmacists, social security, and local health authorities

  • Executives in Clinical Development

  • Health Economics and Outcomes Research leaders

  • Key Questions Answered

  • What kinds of data (e.g., around safety and efficacy) are most useful for improving market access?

  • What are the key differences and common denominators between the payers in the US and key European markets?

  • Who are the best people to represent Pharma in payer negotiations?

  • At what stage of drug development should the payers, or pricing and reimbursement consultants, become involved?

  • What kind of risk-sharing arrangements can be made between pharma and payers?

  • What opportunities are there for win-win collaborations?

  • Expert Views Include:

  • Steve Phillips, director, Health Policy and Reimbursement, Johnson and Johnson — government health policy leader and advisor to all J&J operating companies

  • Tehseen Salimi, vice president, Customer Medical Synergies, Sanofi-Aventis — payer interaction leader, scheduled to speak at Evidence Based Reimbursement Summit 2012

  • Dr. Marcus Wilson, vice president, WellPoint, HealthCore Inc — pioneer in real-world outcomes research

  • Terri Bernacchi, managed care pharmacist/consultant, engaged with several US health plans and IMS Health Managed Market Services — expert and author on payer engagement

  • Michael Hurwich, president, Strategic Pricing Management Group — one of the world’s foremost pricing, revenue & strategy management consultants

  • Cyndy Nayer, president and founder, Center of Health Value Innovation (CHVI) — thought leader on value-based benefit design

  • And many more renowned thought leaders and senior industry executives.

  • Key Quotes

    “It is no longer simply about drug cost but total cost of care to demonstrate a product’s value. Pharma is beginning to understand that.” Dr. Marcus Wilson, vice president, WellPoint, HealthCore Inc

    “If drugmakers haven’t got the relevant health economic data together to support the price of a new drug then it’s never going to float.” Michael Morgan-Curran, director, mHealth Diabetes, GSMA; director/owner, MM-C Innovative Solutions

    “Each payer is different and to create and maintain long term mutually beneficial relationships, pharmaceutical companies must understand a payer’s environment, the way they work, their needs and drivers.” Elliot Rosen, managing director, Accession Healthcare Consultancy

    Table of Contents
    for Pharma and Payers – Building Better Relationships

    • 1. Executive Summary

      2. Introduction

      2.1. Payers: who’s who

      2.2. US payers

      2.3. European payers

      2.4. Payer organisations in the UK (England and Wales)

      2.5. Scotland

      2.6. France

      2.7. Germany

      3.Changing landscape

      3.1. Rapid growth of high-priced biologics and specialty drugs

      3.2. A shift from volume-driven contracts to value-based pricing

      3.3. Patient non-adherence: a costly problem

      3.4. Payers demand real-world data

      3.5. Health economic data: is it good enough for payers?

      3.6. Patient power

      4.The drug manufacturer conundrum

      5.The changing drug manufacturer-payer relationship

      6.What payers want

      6.1. Measuring health outcomes

      6.2. QALY and ICER

      6.3. Comparative effectiveness research, pragmatic clinical trials and adoptive licensing agreements

      6.4. Improving market access via adaptive licensing

      6.5. Market access agreements: health outcomes and risk-sharing schemes

      6.6. Innovative US drug manufacturer-payer alliances and partnerships

      6.7. Building better relationships

      7.The new drugmaker-payer relationship

      7.1. HTA and value-based pricing are here to stay

      7.2. CER is becoming the new normal

      7.3. Quality of economic modelling and health outcomes data is vital

      7.4. Cost of a drug vs cost of care

      7.5. Best-price frameworks

      7.6. When to approach payers

      7.7. Moving From transaction to collaboration builds trust

      7.8. Sharing and exchanging patient data

      8.Opening new communication channels is essential

      8.1 Create an environment of accountability

      9.Moving forward together


    Additional Details


    FirstWord Pharma

    Publisher Information


    25 |

    Number of Pages


    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! The Top 10 Pharma Companies in 2017
    Introduction...leading drivers and resistors to growthWith many of the world's largest pharmaceutica...
    01 Mar 2013 by FirstWord Pharma USD $336 (normally
    USD $395)
    More Info
    SAVE 15% today! Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs
    IntroductionIt’s time to click on this.The media’s dubbed them ‘a doctor in your pocket’ and ‘health...
    01 Feb 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Big Data in Pharma Marketing
    IntroductionBig data - the huge volume of digital data generated worldwide - continues to grow expon...
    01 Jan 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Social and Mobile Pharma - the State of the Digital Landscape
    IntroductionTightly-regulated and conservative in outlook, the pharmaceutical industry has largely b...
    01 Nov 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Pharma Reputations: Managing Perceptions
    IntroductionPharma is no stranger to the idea of nurturing and defending corporate reputations. But...
    01 Aug 2012 by FirstWord Pharma USD $548 (normally
    USD $645)
    More Info
    SAVE 15% today! Pharma's Future Role in CME
    IntroductionOver the last 10 years, every aspect of continuing medical education (CME) has endured m...
    01 Aug 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Pharma sales force shape, size and structure — where next?
    IntroductionRetarget your sales force with new resourcesSales force management now plays a critical ...
    01 Jul 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma
    IntroductionIn 2009, China’s government announced plans to invest RMB1.13 trillion (0 billion) in...
    01 Jun 2012 by FirstWord Pharma USD $846 (normally
    USD $995)
    More Info
    SAVE 15% today! Meeting KOL Needs: What Pharma Needs to Know
    IntroductionThe role of the Key Opinion Leader (KOL) has changed over the past 30 years. And it's ab...
    01 Feb 2012 by FirstWord Pharma USD $1,228 (normally
    USD $1,445)
    More Info
    SAVE 15% today! Academic Detailing: Pharma Fights Back
    IntroductionEver since it was introduced three decades ago, academic detailing—which now increasingl...
    01 Jan 2012 by FirstWord Pharma USD $633 (normally
    USD $745)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Pharma and Payers – Building Better Relationships | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...